Paige vs Shukun 数坤科技
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
Paige
Cancer pathology AI behind the FDA-authorised Paige Prostate, now part...
Visit
|
Shukun 数坤科技
Beijing imaging AI with China's most Class III approvals, by its own c...
Visit
|
|
|---|---|---|
| RECATOOLS Score | 8.2 / 10 | 6.8 / 10 |
| Capability | ||
| Value for money | ||
| Ease of use | ||
| ASEAN readiness | ||
| API quality | ||
| Pricing | Custom | Enterprise |
| Free tier | — | — |
| Paid from | Quoted per deployment; 30-day trial of the diagnostic suites on request | Quoted on request (hospital and distributor sales, trial by application) |
| Has API | ✓ | ✗ |
| Open source | ✗ | ✗ |
| Free to use | ✗ | ✗ |
| Users | In clinical use at hospitals and labs worldwide; training data spans 800+ labs across 45 countries | — |
| Founded | 2017 | 2017 |
| Maker | Tempus AI | — |
| Verdict | Paige has the strongest regulatory record in AI pathology: a 2021 FDA De Novo authorisation for Paige Prostate, Breakthrough designations, and CE and UKCA marks across its suites. The evidence deserves careful reading, t... |
Shukun's case rests on approvals and breadth: 18 Chinese Class III certificates by its count, MDR CE marks across cardiac, stroke and other tools, PMDA approvals in Japan and three FDA 510(k) clearances, including Corona... |
| Full review → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.